Vascular normalization and immunotherapy: Spawning a virtuous cycle

Area of Science:

• Oncology
• Immunology
• Nanomedicine

Background:

• Modern cancer therapy integrates anti-angiogenics, radiotherapy (especially stereotactic body radiotherapy, SBRT), and immunotherapy into a trimodal approach.
• The 'normalization window' presents a critical, albeit brief, opportunity to disrupt cancer cells and enhance treatment efficacy.
• Understanding the tumor microenvironment (TME) and extracellular matrix (ECM) is vital for optimizing therapeutic outcomes.

Purpose of the Study:

• To outline a strategic framework for cancer therapy leveraging the normalization window.
• To detail a stepwise approach for inducing controlled cancer cell death (CCD) and immunological augmentation.
• To emphasize the role of immunotherapy and nanomedicine in enhancing treatment responses and preventing tumor dormancy.

Main Methods:

• Utilizing a trimodal approach including anti-angiogenics, radiotherapy (SBRT), and chemotherapy to induce controlled cancer cell death (CCD) and immunogenic cell death (ICD).
• Timing immunotherapy to coincide with decreased interstitial pressure, improved perfusion, and a more immune-friendly tumor microenvironment (TME).
• Employing adjuvant-assisted neoantigen-immune cell interactions to create a cycle of CCD and tumor-specific immune responses, while protecting the extracellular matrix (ECM).

Main Results:

• The strategic use of the normalization window facilitates controlled cancer cell death (CCD) and immunological augmentation.
• Immunotherapy, initiated during specific physiological conditions, enhances tumor perfusion, immune-friendly pH, and TME infiltration by lymphocytes.
• A synergistic cycle of CCD, antigenic reaction, and vascular normalization is established, with ECM protection crucial for long-term control and preventing dormancy.

Conclusions:

• The trimodal approach, strategically timed around the normalization window, offers a powerful strategy for cancer treatment.
• Optimizing the sequence and timing of therapies, including immunotherapy and nanomedicine, is essential for maximizing treatment benefits.
• Protecting the extracellular matrix is key to fostering long-term immunological memory and preventing tumor recurrence or dormancy.